FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2038978021> ?p ?o ?g. }

• W2038978021 endingPage "1295" @default.
• W2038978021 startingPage "1287" @default.
• W2038978021 abstract "Abstract Background The majority of minimal residual disease (MRD)‐positive patients with acute lymphoblastic leukemia (ALL) have poor outcomes. The ALL2000 study was performed to evaluate the efficacy of augmented chemotherapy based on MRD‐restratification in childhood ALL. Procedure Between 2000 and 2004, 305 eligible patients with precursor B or T‐cell ALL were enrolled in the ALL2000 study. The ALL941‐based therapy protocol utilized PCR MRD assays using Immunoglobulin and T‐cell receptor gene rearrangements. They were initially stratified into three risk‐groups according to leukocyte count and age, and MRD levels were measured at weeks 5 (TP1) and 12 (TP2) for a second stratification. From week 14, patients with MRD levels $ mathbin{lower.3exhbox{$buildrel>over {smash{scriptstyle=}vphantom{_x}}$}} 10^{ - 3} $ received an increase in therapy (one risk group higher), while the remainder continued to receive the initial risk‐adapted therapy. Results The overall 5‐year event‐free survival (EFS) rate for ALL2000 was 79.7 ± 2.4%. MRD stratification was feasible for 234 of 301 patients (77%) who achieved complete remission. The EFS rate of the MRD stratifiable (MRD) group was 82.5 ± 2.6%, considerably superior to the 74.7 ± 5.7% of MRD non‐stratifiable (Non‐MRD) group ( P = 0.084) and the 74.4 ± 2.1% for ALL 941 ( P = 0.012). MRD‐positive patients at TP2 showed inferior outcomes as compared with MRD‐negative cases, but the difference did not reach a statistically significant level in any risk groups or immunophenotypes. Conclusions These results suggest that augmented therapy for MRD‐positive patients at TP2 contributed to better outcomes of the ALL2000 study. Pediatr Blood Cancer. 2010;55:1287–1295. © 2010 Wiley‐Liss, Inc." @default.
• W2038978021 created "2016-06-24" @default.
• W2038978021 creator A5013300560 @default.
• W2038978021 creator A5013531934 @default.
• W2038978021 creator A5016475153 @default.
• W2038978021 creator A5017179381 @default.
• W2038978021 creator A5029680324 @default.
• W2038978021 creator A5030491895 @default.
• W2038978021 creator A5031329064 @default.
• W2038978021 creator A5033169481 @default.
• W2038978021 creator A5035749444 @default.
• W2038978021 creator A5036509995 @default.
• W2038978021 creator A5040240441 @default.
• W2038978021 creator A5045756211 @default.
• W2038978021 creator A5049077837 @default.
• W2038978021 creator A5054178612 @default.
• W2038978021 creator A5069874057 @default.
• W2038978021 creator A5070890725 @default.
• W2038978021 creator A5076453570 @default.
• W2038978021 creator A5080093171 @default.
• W2038978021 creator A5080909567 @default.
• W2038978021 creator A5086147523 @default.
• W2038978021 creator A5089196061 @default.
• W2038978021 date "2010-10-25" @default.
• W2038978021 modified "2023-10-11" @default.
• W2038978021 title "Minimal residual disease-based augmented therapy in childhood acute lymphoblastic leukemia: A report from the Japanese Childhood Cancer and Leukemia Study Group" @default.
• W2038978021 cites W1904793007 @default.
• W2038978021 cites W1968151924 @default.
• W2038978021 cites W1977632364 @default.
• W2038978021 cites W1986395681 @default.
• W2038978021 cites W1987538151 @default.
• W2038978021 cites W1993637374 @default.
• W2038978021 cites W2014804837 @default.
• W2038978021 cites W2019471283 @default.
• W2038978021 cites W2020564710 @default.
• W2038978021 cites W2024667104 @default.
• W2038978021 cites W2070434896 @default.
• W2038978021 cites W2074181164 @default.
• W2038978021 cites W2075139424 @default.
• W2038978021 cites W2087182733 @default.
• W2038978021 cites W2092925278 @default.
• W2038978021 cites W2095893307 @default.
• W2038978021 cites W2099867002 @default.
• W2038978021 cites W2100025372 @default.
• W2038978021 cites W2151069914 @default.
• W2038978021 cites W2152285805 @default.
• W2038978021 cites W2171481279 @default.
• W2038978021 cites W2254760154 @default.
• W2038978021 cites W2313577290 @default.
• W2038978021 cites W2546964172 @default.
• W2038978021 cites W59733412 @default.
• W2038978021 doi "https://doi.org/10.1002/pbc.22620" @default.
• W2038978021 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20535816" @default.
• W2038978021 hasPublicationYear "2010" @default.
• W2038978021 type Work @default.
• W2038978021 sameAs 2038978021 @default.
• W2038978021 citedByCount "39" @default.
• W2038978021 countsByYear W20389780212012 @default.
• W2038978021 countsByYear W20389780212013 @default.
• W2038978021 countsByYear W20389780212014 @default.
• W2038978021 countsByYear W20389780212015 @default.
• W2038978021 countsByYear W20389780212016 @default.
• W2038978021 countsByYear W20389780212018 @default.
• W2038978021 countsByYear W20389780212019 @default.
• W2038978021 countsByYear W20389780212020 @default.
• W2038978021 countsByYear W20389780212021 @default.
• W2038978021 countsByYear W20389780212022 @default.
• W2038978021 countsByYear W20389780212023 @default.
• W2038978021 crossrefType "journal-article" @default.
• W2038978021 hasAuthorship W2038978021A5013300560 @default.
• W2038978021 hasAuthorship W2038978021A5013531934 @default.
• W2038978021 hasAuthorship W2038978021A5016475153 @default.
• W2038978021 hasAuthorship W2038978021A5017179381 @default.
• W2038978021 hasAuthorship W2038978021A5029680324 @default.
• W2038978021 hasAuthorship W2038978021A5030491895 @default.
• W2038978021 hasAuthorship W2038978021A5031329064 @default.
• W2038978021 hasAuthorship W2038978021A5033169481 @default.
• W2038978021 hasAuthorship W2038978021A5035749444 @default.
• W2038978021 hasAuthorship W2038978021A5036509995 @default.
• W2038978021 hasAuthorship W2038978021A5040240441 @default.
• W2038978021 hasAuthorship W2038978021A5045756211 @default.
• W2038978021 hasAuthorship W2038978021A5049077837 @default.
• W2038978021 hasAuthorship W2038978021A5054178612 @default.
• W2038978021 hasAuthorship W2038978021A5069874057 @default.
• W2038978021 hasAuthorship W2038978021A5070890725 @default.
• W2038978021 hasAuthorship W2038978021A5076453570 @default.
• W2038978021 hasAuthorship W2038978021A5080093171 @default.
• W2038978021 hasAuthorship W2038978021A5080909567 @default.
• W2038978021 hasAuthorship W2038978021A5086147523 @default.
• W2038978021 hasAuthorship W2038978021A5089196061 @default.
• W2038978021 hasConcept C126322002 @default.
• W2038978021 hasConcept C143998085 @default.
• W2038978021 hasConcept C187212893 @default.
• W2038978021 hasConcept C2776694085 @default.
• W2038978021 hasConcept C2778461978 @default.
• W2038978021 hasConcept C2779823535 @default.
• W2038978021 hasConcept C2909962599 @default.
• W2038978021 hasConcept C3018657049 @default.

• next